FedEx Corporation (NYSE:FDX) after botching some deliveries for Huawei Technologies Co., filed a lawsuit Monday to stop the U.S. government from requiring the package giant to enforce a crackdown on the Chinese telecommunications-gear maker. The lawsuit, filed in a federal court in Washington, D.C., claims the U.S. Commerce Department’s latest restrictions are essentially forcing FedEx to police millions of packages it ships daily to ensure prohibited items aren’t being exported to Huawei. It is a task, FedEx claims, that is legally and logistically impossible.
FedEx Corporation (NYSE:FDX), a Services sector firm, traded 3.55 Million shares in last trading session with closing price of $160.90 per share. Company gross margin stands at 70.60% whereas its return on investment (ROI) is 9.60%. Stock value has moved between $150.37 – 259.52 in last one year. Analyst’s mean target price for FedEx Corporation (NYSE:FDX) is $205.21 while analysts mean recommendation is 2.10. FDX EPS growth this year is -2.30%.
On last trading day, At Home Group Inc. (NYSE:HOME) shares closed at $6.80 per share. HOME market capitalization is 440.16. Analyst’s mean target price for At Home Group Inc. (NYSE:HOME) is $18.73 whereas analysts mean recommendation is 2.00. Its weekly performance is -12.71% while year to date (YTD) performance is -63.56%.
In last session Arbutus Biopharma Corporation (NASDAQ:ABUS) traded 731832 shares and was closed at $2.18. Analyst’s mean target price for ABUS is $9.32 while analysts mean recommendation is 1.90. Company is -82.70% away from its 52 week high and is moving 53.52% ahead of its 52 week low. ABUS return on assets is -30.60%. Arbutus Biopharma Corporation (NASDAQ:ABUS) quarterly performance is -39.28% while its price to sale ratio is 25.57.
Addus HomeCare Corporation (NASDAQ:ADUS), a Healthcare sector firm, traded 97382 shares on last trading day with closing price of $74.54 per share. Company gross margin stands at 27.00% whereas its return on investment (ROI) is 6.80%. Stock value has moved between $55.21 – 77.65 in last one year. Analyst’s mean target price for Addus HomeCare Corporation (NASDAQ:ADUS) is $80.00 while analysts mean recommendation is 1.30. ADUS EPS growth this year is 20.50%.